CRNX · Insider Trading
Crinetics Pharmaceuticals, Inc.
Every open-market purchase and sale reported by CRNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Weston Nichols | Director | D | −22,225 | −$1.89M |
| 2026-09-01 | Coelho Rogerio Vivaldi | Director | D | −19,225 | −$1.63M |
| 2026-09-01 | Isabel Kalofonos | Chief Commercial Officer | D | −35,669 | −$3.03M |
| 2026-09-01 | Matthew K Fust | Director | D | −28,761 | −$2.44M |
| 2026-09-01 | Tobin Schilke | Chief Financial & Infra. Ofcr. | D | −79,427 | −$6.75M |
| 2026-09-01 | Richard Scott Struthers | President & CEO | D | −1,402,911 | −$119.25M |
| 2026-09-01 | Camille L Bedrosian | Director | D | −22,225 | −$1.89M |
| 2026-09-01 | Wendell Wierenga | Director | D | −122,071 | −$10.38M |
| 2026-09-01 | Stephanie Okey | Director | D | −12,325 | −$1.05M |
| 2026-09-01 | Stephen F. Betz | Chief Scientific Officer | D | −137,936 | −$11.72M |
| 2026-09-01 | Caren Deardorf | Director | D | −22,225 | −$1.89M |
| 2026-08-24 | Tobin Schilke | Chief Financial & Infra. Ofcr. | A | +471 | — |
| 2026-08-11 | Richard Scott Struthers | President & CEO | M | +19,928 | +$399.99K |
| 2026-07-07 | Coelho Rogerio Vivaldi | Director | Sell | −3,000 | −$120.00K |
| 2026-06-22 | Coelho Rogerio Vivaldi | Director | A | +5,925 | — |
| 2026-06-22 | Camille L Bedrosian | Director | A | +5,925 | — |
| 2026-06-22 | Wendell Wierenga | Director | A | +5,925 | — |
| 2026-06-22 | Caren Deardorf | Director | A | +5,925 | — |
| 2026-06-22 | Stephanie Okey | Director | A | +5,925 | — |
| 2026-06-22 | Matthew K Fust | Director | A | +5,925 | — |
| 2026-06-22 | Weston Nichols | Director | A | +5,925 | — |
| 2026-06-18 | Stephanie Okey | Director | Sell | −6,900 | −$246.14K |
| 2026-06-02 | Richard Scott Struthers | President & CEO | G | — | — |
| 2026-04-10 | Jeff E. Knight | Chief Dev. & Operating Officer | MIXED | −6,729 | −$1.66M |
| 2026-03-18 | Stephen F. Betz | Chief Scientific Officer | Sell | −10,612 | −$396.61K |
| 2026-03-18 | Jeff E. Knight | Chief Operating Officer | Sell | −9,911 | −$370.41K |
| 2026-03-18 | Richard Scott Struthers | President & CEO | Sell | −21,981 | −$821.51K |
| 2026-03-13 | Coelho Rogerio Vivaldi | Director | Sell | −5,000 | −$180.76K |
| 2026-03-04 | Stephanie Okey | Director | Sell | −3,000 | −$119.01K |
| 2026-03-04 | Tobin Schilke | Chief Financial Officer | Sell | −6,713 | −$266.30K |
| 2026-02-25 | Isabel Kalofonos | Chief Commercial Officer | A | +34,000 | — |
| 2026-02-25 | Stephen F. Betz | Chief Scientific Officer | A | +30,000 | — |
| 2026-02-25 | Richard Scott Struthers | President & CEO | A | +62,000 | — |
| 2026-02-25 | Jeff E. Knight | Chief Operating Officer | A | +34,000 | — |
| 2026-02-25 | Tobin Schilke | Chief Financial Officer | A | +32,000 | — |
| 2026-01-07 | Isabel Kalofonos | Chief Commercial Officer | MIXED | — | −$36.02K |
| 2025-12-29 | Stephen F. Betz | Chief Scientific Officer | M | +18,000 | +$34.38K |
| 2025-12-18 | Richard Scott Struthers | President & CEO | M | +44,742 | +$585.89K |
| 2025-12-03 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | −$140.65K |
| 2025-11-05 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | −$128.86K |
| 2025-10-03 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | −$124.60K |
| 2025-09-30 | Richard Scott Struthers | President & CEO | Sell | −4,000 | −$180.00K |
| 2025-09-30 | Matthew K Fust | Director | MIXED | −6,000 | −$696.90K |
| 2025-09-04 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | −$76.05K |
| 2025-08-26 | Dana Pizzuti | Chief Med and Dev Officer | MIXED | — | −$406.20K |
| 2025-08-21 | Dana Pizzuti | Chief Med and Dev Officer | Sell | −6,492 | −$189.44K |
| 2025-06-16 | Stephen F. Betz | Chief Scientific Officer | MIXED | −9,313 | −$2.85M |
| 2025-06-13 | Stephanie Okey | Director | A | +6,900 | — |
| 2025-06-13 | Matthew K Fust | Director | A | +6,900 | — |
| 2025-06-13 | Camille L Bedrosian | Director | A | +6,900 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jeff E. Knight | Chief Dev. & Operating Officer | 190,452 | $16.18M |
| Wendall Wierenga | Director | 116,146 | $9.87M |
| Dana Pizzuti | Chief Med and Dev Officer | 66,837 | $5.68M |
| Matthew K Fust | Director | 5,925 | $503.33K |
| Coelho Rogerio Vivaldi | Director | 5,925 | $503.33K |
| Weston Nichols | Director | 5,925 | $503.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CRNX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.